Skip to main content

Metabolon, MGH Partner on Biomarker Discovery for Type I Diabetes

NEW YORK, March 29 (GenomeWeb News) - Metabolon and Massachusetts General Hospital hope to co-discover biomarkers for diabetic nephropathy in type I diabetes, Metabolon said today.

 

The study has been funded by a two-year grant awarded to MGH's Darryl Palmer-Toy by the National Institute of Diabetes and Digestive and Kidney Diseases. The amount of funding for fiscal year 2004, which began on Oct.  1, is worth $365,000.

 

Metabolon will test patient urine and plasma samples with its metabolomics platform to search for signatures that predict the likelihood of developing diabetic nephropathy, Metabolon said.

 

This is the second collaboration announced between Metabolon and MGH in the past year. In August, Metabolon and MGH announced a collaborative biomarker study for amyotrophic lateral sclerosis.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.